导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 5.57% | 1233/4773 |
| 近一周 | -1.11% | 1696/5465 |
| 近一月 | -1.56% | 1192/5421 |
| 近一季 | 0.07% | 990/5231 |
| 近半年 | 3.55% | 922/4920 |
| 近一年 | 8.15% | 1371/4394 |
| 近两年 | 46.17% | 1628/2954 |
| 近三年 | 30.55% | 1073/2253 |
| 成立以来 | 164.27% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.05% 3014/4961 |
9.79% 2463/5312 |
- - |
- - |
| 2025 | 15.13% 2569/4813 |
0.21% 1945/3635 |
1.80% 2129/4076 |
11.66% 3142/4524 |
1.08% 1551/4813 |
| 2024 | 15.92% 865/3463 |
3.06% 629/2808 |
- 664/3014 |
13.70% 2131/3129 |
-1.07% 1577/3463 |
| 2023 | -10.93% 1352/2656 |
1.37% 1583/2280 |
-5.04% 1354/2385 |
-0.91% 462/2515 |
-6.62% 1849/2655 |
| 2022 | -17.30% 571/2207 |
-12.44% 610/1919 |
6.00% 793/2016 |
-12.52% 718/2113 |
1.86% 1114/2208 |
| 2021 | -5.21% 971/1822 |
-2.60% 677/1255 |
4.69% 855/1330 |
-5.95% 879/1466 |
-1.16% 1322/1822 |
| 2020 | 43.33% 247/1250 |
-8.90% 637/1028 |
16.53% 431/1067 |
18.18% 84/1164 |
14.24% 288/1184 |
| 2019 | 20.58% 663/1092 |
12.99% 700/754 |
-0.71% 283/804 |
0.39% 520/850 |
7.06% 492/918 |
| 2018 | -19.39% 163/834 |
- - |
- - |
- - |
-10.31% 186/691 |
| 2017 | 17.83% 217/714 |
- - |
- - |
- - |
- - |
| 2016 | 1.99% 87/605 |
- - |
- - |
- - |
- - |
| 2015 | 32.14% 72/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 国泰沪深300指数增强A VS. 长安沪深300非周期A(740101) |